Bioxyne Limited has announced a new manufacturing agreement with Aurora Cannabis Inc., placing manufacturing at the center of a partnership aimed at supplying pharmaceutical-grade cannabis products to multiple international markets.
In an ASX statement, Bioxyne Limited said its wholly owned subsidiary, Breathe Life Sciences, will manufacture medicinal cannabis products under Good Manufacturing Practice (GMP) standards as part of the agreement with the Canadian-based producer.
The company stated the initial phase of the manufacturing agreement covers the supply of GMP-certified medicinal cannabis oils to Australia, noting that “initial deliveries [have] already [been] completed.”
The scope is also being expanded to include GMP-manufactured cannabis vape products intended for distribution in Australia, the United Kingdom and Germany.
Bioxyne described the agreement as a step forward in its manufacturing strategy, saying it “underscores [its] growing credibility as a global player in pharmaceutical-grade cannabis manufacturing and its ability to deliver high-quality, scalable solutions.”
Chief Executive Officer Sam Watson said the deal represents a milestone for the company’s manufacturing operations. “This partnership with Aurora represents a significant milestone for BLS as we expand our manufacturing capabilities,” Watson said.
“We are excited about the potential of our broader product portfolio across multiple international markets. This agreement validates our pharmaceutical manufacturing expertise and positions us well for growth.”
Aurora Cannabis also highlighted the manufacturing focus of the collaboration, particularly in strengthening supply chains. Alex Miller, Executive Vice President, Operations & Supply Chain at Aurora, said: “As a global leader in medical cannabis, we’re focused on building a resilient, high-quality supply chain across key international markets. BLS brings strong GMP-manufacturing capabilities that complement our scale, regulatory scrutiny and commitment to delivering high quality medical cannabis products to patients.”
According to the release, the agreement has an initial 12-month rolling term with automatic renewal, and can be terminated with six months’ notice. Both companies have begun onboarding additional product lines, with discussions ongoing regarding further manufacturing and supply opportunities across the same international markets.
Bioxyne said the agreement reflects its progression from an Australian-based manufacturer to a participant in global pharmaceutical cannabis supply, while Aurora framed the partnership as part of its broader effort to maintain consistent product quality and supply across regulated markets.
The content of this article is based on information supplied by Bioxyne Limited. For more information, please refer to the official company announcement and communications from Bioxyne. Please consult a licensed and/or registered professional in this area before making any decisions based on the content of this article.
